Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 240

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 240
---
 contingent consideration charges (gains), acquisition-related expenses, restructuring and other during the periods indicated, including percent changes (dollar amounts in thousands): 

Three Months EndedSeptember 30,% Increase / (Decrease)Nine Months EndedSeptember 30,% Increase / (Decrease)2025202420252024Contingent consideration charges (gains)$625 $(3,244)N/A$(2,407)$(5,541)(57)%Restructuring charges3,728 1,193 100+%3,728 7,724 (52)%Acquisition-related expenses(280)285 N/A2,222 689 100+%Legal settlement— — N/A7,000 — N/ALegal judgment(23,148)— N/A(23,148)— N/AImpairment of acquired in-process research & development (IPR&D)25,866 — N/A25,866 — N/ATotal contingent consideration charges (gains), acquisition-related expenses, restructuring and other$6,791 $(1,766)N/A$13,261 $2,872 100+%

During the three and nine months ended September 30, 2025, total contingent consideration charges (gains), acquisition-related expenses, restructuring and other included net charges of $6.8 million and $13.3 million, respectively. During the three and nine months ended September 30, 2024, total contingent consideration charges (gains), acquisition-related expenses, restructuring and other included net gains of $1.8 million and net charges of $2.9 million, respectively.

During the three months ended September 30, 2025, we recognized contingent consideration charges of $0.6 million due revisions to the latest discount rates, partially offset by a reduction in the sales forecast through the milestone expiration date of December 31, 2030. During the nine months ended September 30, 2025, we recognized contingent consideration gains of $2.4 million due to revisions to the latest discount rates.

During the three and nine months ended September 30, 2024, we recognized contingent consideration gains of $3.2 million and $5.5 million, respectively, primarily due to adjustments reflecting the probability of achieving the remaining Flexion regulatory milestone by the milestone expiration date, partially offset by revisions to the latest discount rates.

In July 2025, as a result of improving manufacturing efficiencies for